Thomas N Wight1, Michael G Kinsella2, Stephen P Evanko2, Susan Potter-Perigo2, Mervyn J Merrilees3. 1. Matrix Biology Program, Benaroya Research Institute at Virginia Mason, Seattle, WA, USA. Electronic address: twight@benaroyaresearch.org. 2. Matrix Biology Program, Benaroya Research Institute at Virginia Mason, Seattle, WA, USA. 3. Department of Anatomy with Radiology, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
Abstract
BACKGROUND: Versican is an extracellular matrix (ECM) proteoglycan that is present in the pericellular environment of most tissues and increases in many different diseases. Versican interacts with cells to influence the ability of cells to proliferate, migrate, adhere and assemble an ECM. SCOPE OF REVIEW: The structure of the versican molecule is briefly reviewed and studies highlighting those factors that promote versican synthesis and degradation and their impact on cell phenotype in disease are discussed. Particular attention is given to vascular disease, but other diseases where versican is important are covered as well, most notably different forms of cancers. Attention is given to mechanisms(s) by which versican influences cell behaviors through either direct or indirect processes. Versican produced by either stromal cells or myeloid cells can have a major impact influencing immunity and inflammation. Finally, studies controlling versican accumulation that either delay or inhibit the progression of disease will be highlighted. MAJOR CONCLUSIONS: Versican is one component of the ECM that can influence the ability of cells to proliferate, migrate, adhere, and remodel the ECM. Targeting versican as a way to control cell phenotype offers a novel approach in the treatment of disease. SIGNIFICANCE: ECM molecules such as versican contribute to the structural integrity of tissues and interact with cells through direct and indirect means to regulate, in part, cellular events that form the basis of disease. This article is part of a Special Issue entitled Matrix-mediated cell behaviour and properties.
BACKGROUND:Versican is an extracellular matrix (ECM) proteoglycan that is present in the pericellular environment of most tissues and increases in many different diseases. Versican interacts with cells to influence the ability of cells to proliferate, migrate, adhere and assemble an ECM. SCOPE OF REVIEW: The structure of the versican molecule is briefly reviewed and studies highlighting those factors that promote versican synthesis and degradation and their impact on cell phenotype in disease are discussed. Particular attention is given to vascular disease, but other diseases where versican is important are covered as well, most notably different forms of cancers. Attention is given to mechanisms(s) by which versican influences cell behaviors through either direct or indirect processes. Versican produced by either stromal cells or myeloid cells can have a major impact influencing immunity and inflammation. Finally, studies controlling versican accumulation that either delay or inhibit the progression of disease will be highlighted. MAJOR CONCLUSIONS:Versican is one component of the ECM that can influence the ability of cells to proliferate, migrate, adhere, and remodel the ECM. Targeting versican as a way to control cell phenotype offers a novel approach in the treatment of disease. SIGNIFICANCE: ECM molecules such as versican contribute to the structural integrity of tissues and interact with cells through direct and indirect means to regulate, in part, cellular events that form the basis of disease. This article is part of a Special Issue entitled Matrix-mediated cell behaviour and properties.
Authors: Dingcheng Gao; Natasha Joshi; Hyejin Choi; Seongho Ryu; Mary Hahn; Raul Catena; Helen Sadik; Pedram Argani; Patrick Wagner; Linda T Vahdat; Jeffrey L Port; Brendon Stiles; Saraswati Sukumar; Nasser K Altorki; Shahin Rafii; Vivek Mittal Journal: Cancer Res Date: 2012-01-26 Impact factor: 12.701
Authors: Daniel Y Lee; Tatiana Shatseva; Zina Jeyapalan; William W Du; Zhaoqun Deng; Burton B Yang Journal: PLoS One Date: 2009-02-18 Impact factor: 3.240
Authors: Terence N Bukong; Sean B Maurice; Barinder Chahal; David F Schaeffer; Paul J Winwood Journal: Lab Invest Date: 2016-01-11 Impact factor: 5.662
Authors: Thomas N Wight; Charles W Frevert; Jason S Debley; Stephen R Reeves; William C Parks; Steven F Ziegler Journal: Cell Immunol Date: 2016-12-23 Impact factor: 4.868
Authors: Paul A Keire; Steven L Bressler; Eileen R Mulvihill; Barry C Starcher; Inkyung Kang; Thomas N Wight Journal: Matrix Biol Date: 2015-12-23 Impact factor: 11.583
Authors: Jessica M Snyder; Ida M Washington; Timothy Birkland; Mary Y Chang; Charles W Frevert Journal: J Histochem Cytochem Date: 2015-09-18 Impact factor: 2.479
Authors: Stephen R Reeves; Gernot Kaber; Alyssa Sheih; Georgiana Cheng; Mark A Aronica; Mervyn J Merrilees; Jason S Debley; Charles W Frevert; Steven F Ziegler; Thomas N Wight Journal: J Histochem Cytochem Date: 2016-04-28 Impact factor: 2.479